Buy Norepinephrine Agetan solution concentrate 2 mg/ml ampoules 4 ml 10 pcs packaging
  • Buy Norepinephrine Agetan solution concentrate 2 mg/ml ampoules 4 ml 10 pcs packaging


1793 Items
Dosage form
Brand & Manufacturer
Package Size
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Noradrenaline Agetan - adrenomimetic.


Α agonistl- and α2-adrenergic receptors. It slightly excites β1- and practically does not affect β2-adrenoreceptors. It has a powerful vasoconstrictor effect, leading to an increase in AD.


Not absorbed in the digestive tract. When i / v introduction quickly reaches Cmax in plasma (within 2–3 min).

It is metabolized in the liver, kidney and blood plasma with the participation of MAO and catechol-O-methyltransferase (COMT) to practically inactive metabolites, which are excreted through the kidneys.


Acute hypotension accompanying cardiovascular collapse and shock (to restore and maintain blood pressure - IV perfusion).


1 ml. contains:

Active substance: norepinephrine tartrate monohydrate (in terms of norepinephrine tartrate) 2 mg / ml;

Excipients: sodium chloride; sodium hydroxide or hydrochloric acid (pH = 3.0–4.5); water for injections.

Norepinephrine is marketed under different brands and generic names, and comes in different dosage forms:

Brand nameManufacturerCountryDosage form
Norepinephrine Agetan EcoPharmPlus Russia solution concentrate
Norepinephrine Agetan Laboratory Agetan France ampoules

No customer reviews for the moment.

Write your review

Write your review


Dosage and Administration

Intravenously, preferably in the vein of the elbow.

The concentrate should be diluted in 5% glucose solution or 0.9% sodium chloride solution. Do not mix with other drugs. With the introduction of Noradrenaline Agetan, you need to constantly monitor blood pressure and heart rate.

After diluting the concentrate, the solution should be used within 12 hours.

An individual dose is established depending on the clinical condition of the patient. The initial dose and rate of administration from 0.1 to 0.3 μg / kg / min of norepinephrine tartrate is recommended. The maximum dose and rate of administration used in the treatment of septic and hemorrhagic shock can reach 3–5 μg / kg / min.

Adverse reactions

With the introduction of Noradrenalin Agetan, the following symptoms may occur:


  • ischemic disorders up to necrosis caused by vasoconstriction and hypoxia of the tissues, as well as due to extravasation;
  • arrhythmia;
  • reflex bradycardia;
  • anxiety;
  • difficulty breathing;
  • tremor;
  • transient headache;
  • chest or pharyngeal pain;
  • vegetative reactions - pallor, increased sweating, vomiting, tachycardia. In particularly sensitive patients, an increase in blood pressure may be accompanied by headache, photophobia, stabbing chest pain, pallor of the skin, increased sweating and vomiting.

With prolonged use, dose adjustment is necessary to avoid recurrent hypotension with drug withdrawal.


  • severe left ventricular failure, acute heart failure, recent myocardial infarction;
  • simultaneous use of imipramine and triptilin MAO inhibitors (due to the risk of a pronounced and prolonged increase in blood pressure);
  • development of cardiac arrhythmia symptoms (in this case, a reduction in the dose of the drug is necessary). In case of polymorphic extrasystoles or the development of volleys of extrasystoles, the dose of the drug should be significantly reduced or canceled treatment.

Drug interactions

The main undesirable effects when combined with certain groups of drugs are pharmacodynamic.

When combined with inhaled anesthetic agents, serious ventricular arrhythmias can occur (anxiety of the heart).

When combined with serotonergic and adrenergic antidepressants, as well as derivatives of imipramine and amitriptyline, paroxysmal hypertension may develop with a risk of cardiac arrhythmia due to adreno-blocking effect on the sympathetic nervous system.

The combination of Noradrenaline Agetan with selective and non-selective MAO inhibitors, linezolid, is contraindicated. at the same time there is a synergistic enhancement of the pressor action of norepinephrine, which requires careful medical monitoring.

Pregnancy and Lactation

Pregnancy is not a restriction for the use of Noradrenaline Agetan. At the time of treatment should stop breastfeeding (no experience with the use of the drug in lactating women).


Symptoms: there may be a spasm of skin vessels, collapse, anuria, a pronounced increase in blood pressure.

Treatment: with manifestations of overdose, the dose should be reduced.

  • Brand name: Norepinephrine Agetan
  • Active ingredient: Norepinephrine
  • Dosage form: Concentrate for solution for intravenous administration
  • Manufacturer: EcoPharmPlus
  • Country of Origin: Russia

Studies and clinical trials of Norepinephrine (Click to expand)

  1. Systematic search for variation in the human norepinephrine transporter gene: Identification of five naturally occurring missense mutations and study of association with major psychiatric disorders
  2. Correlation between morphometric differences and norepinephrine content in benign prostatic hyperplasia
  3. Functional property, norepinephrine content and morphometric findings in human hyperplastic prostate
  4. Effects of environment on tissue norepinephrine concentration in chum salmon (Oncorhynchus keta)
  5. Tissue norepinephrine depletion as a mechanism for calcium chloride inhibition of gastric carcinogenesis in rats after treatment with N-methyl-N<′-nitro-N-nitrosoguanidine and sodium chloride
  6. Regulation of norepinephrine release from the rat bed nucleus of the stria terminalis: In vivo microdialysis studies
  7. GABA induces norepinephrine exocytosis from hippocampal noradrenergic axon terminals by a dual mechanism involving different voltage-sensitive calcium channels
  8. Characterization of caveolae from rat heart: Localization of postreceptor signal transduction molecules and their rearrangement after norepinephrine stimulation
  9. Growth-promoting effects of Ca2+-mobilizing agents in hepatocytes: Lack of correlation between the acute activation of phosphoinositide-specific phospholipase C and the stimulation of DNA synthesis by angiotensin II, vasopressin, norepinephrine, and prostaglandin F2α
  10. Excitatory and inhibitory actions of norepinephrine on the Ba2+ current through L-type Ca2+ channels of smooth muscle cells of guinea-pig vas deferens
  11. Activation of p42/p44 mitogen-activated protein kinase by angiotensin II, vasopressin, norepinephrine, and prostaglandin F2α in hepatocytes is sustained, and like the effect of epidermal growth factor, mediated through pertussis toxin-sensitive mechanisms
  12. Role of diacylglycerol (DAG) in hormonal induction of S phase in hepatocytes: The DAG-dependent protein kinase C pathway is not activated by epidermal growth factor (EGF), but is involved in mediating the enhancement of responsiveness to EGF by vasopressin, angiotensin II, and norepinephrine
  13. Neurotrophin-3- and norepinephrine-mediated adrenergic differentiation and the inhibitory action of desipramine and cocaine
  14. Role of N- and L-type calcium channels in depolarization-induced activation of tyrosine hydroxylase and release of norepinephrine by sympathetic cell bodies and nerve terminals
  15. Effect of 17β-estradiol and the nonsteroidal benzothiophene, LY117018 on in vitro rat aortic responses to norepinephrine, serotonin, U46619, and BAYK 8644
  16. Norepinephrine promotes long-term potentiation in the adult rat hippocampus in vitro
  17. Castration differentially alters [3H]nisoxetine binding to norepinephrine uptake sites in olfactory bulb and frontal cortex of male rats
  18. Discrete local application of corticotropin-releasing factor increases locus coeruleus discharge and extracellular norepinephrine in rat hippocampus
  19. Enantiomeric separation of d-/l-norepinephrine and -epinephrine by high-performance liquid chromatography with a β-cyclodextrin type chiral stationary phase
  20. Preparation of 4- and 6-[76Br] bromometaraminol, two potential radiotracers for the study of the myocardial norepinephrine neuronal reuptake system with PET
  21. Secretion of various endocrine substances by acth-secreting tumors—gastrin, melanotropin, norepinephrine, serotonin, parathormone, vasopressin, glucagon
  22. Norepinephrine-producing tumors of bilateral breasts. A case report
  23. Dopamine, norepinephrine and serotonin production by an intestinal carcinoid tumor
  24. Effect of standardized test meals on plasma norepinephrine in patients with anorexia nervosa and bulimia

8 other products in the same category: